^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pegylated liposomal doxorubicin

    i
    Other names: Doxorubicin Hydrochloride Cytori, ATI-0918, Dox-SL, SPI 49, JNS-002, TLC177, TLC 177
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    4d
    Actuate 1801: 9-ING-41 in Patients With Advanced Cancers (clinicaltrials.gov)
    P2, N=350, Active, not recruiting, Actuate Therapeutics Inc. | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • irinotecan • pegylated liposomal doxorubicin • lomustine • elraglusib (9-ING-41)
    5d
    R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse (clinicaltrials.gov)
    P2, N=83, Recruiting, Fudan University | Trial completion date: Jan 2028 --> Dec 2028 | Trial primary completion date: Jan 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • pegylated liposomal doxorubicin
    6d
    TREVI-OC-01: AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=289, Recruiting, AstraZeneca | N=46 --> 289
    Enrollment change • Platinum resistant
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • torvutatug samrotecan (AZD5335)
    6d
    CLLRT2: A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with DLBCL-type Richter Transformation (2024-513445-37-00)
    P2/3, N=57, Not yet recruiting, University Of Cologne
    New P2/3 trial
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp)
    6d
    Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy (clinicaltrials.gov)
    P2, N=87, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Avastin (bevacizumab) • carboplatin • gemcitabine • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    8d
    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (clinicaltrials.gov)
    P1, N=68, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | Trial completion date: Jun 2027 --> Dec 2027
    Enrollment closed • Trial completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • temozolomide • cytarabine • etoposide IV • pegylated liposomal doxorubicin • dexamethasone
    10d
    Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas (clinicaltrials.gov)
    P1, N=24, Recruiting, Case Comprehensive Cancer Center | Trial primary completion date: Apr 2026 --> Sep 2026
    Trial primary completion date
    |
    pegylated liposomal doxorubicin
    17d
    Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=36, Recruiting, SCRI Development Innovations, LLC | Trial completion date: Jul 2026 --> Nov 2027 | Trial primary completion date: Jul 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    Tukysa (tucatinib) • pegylated liposomal doxorubicin
    18d
    Combination Therapy for Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=72, Recruiting, Sham Sunder Kakar | Trial completion date: Nov 2027 --> Nov 2028 | Trial primary completion date: Nov 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    pegylated liposomal doxorubicin
    19d
    A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, GlaxoSmithKline | Trial completion date: Jan 2030 --> Jul 2030 | Initiation date: Mar 2026 --> Jun 2026 | Trial primary completion date: Jan 2030 --> Jul 2030
    Trial completion date • Trial initiation date • Trial primary completion date • Platinum resistant
    |
    VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • mocertatug rezetecan (GSK5733584)
    20d
    CLLRT2: A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with DLBCL-type Richter Transformation (2024-513445-37-00)
    P2/3, N=41, Not yet recruiting, University Of Cologne
    New P2/3 trial
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp)
    21d
    ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Michael Spinner, MD | Trial completion date: Apr 2033 --> Oct 2033 | Initiation date: Oct 2025 --> May 2026 | Trial primary completion date: Oct 2028 --> Mar 2029
    Trial completion date • Trial initiation date • Trial primary completion date • Circulating tumor DNA
    |
    Foresight CLARITY™
    |
    Keytruda (pembrolizumab) • gemcitabine • pegylated liposomal doxorubicin • Neulasta (pegfilgrastim)